NASDAQ:VTL - Vital Therapies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.45 +0.55 (+6.96 %)
(As of 07/19/2018 04:00 PM ET)
Previous Close$7.90
Today's Range$7.85 - $8.50
52-Week Range$2.42 - $8.81
Volume365,500 shs
Average Volume245,544 shs
Market Capitalization$338.95 million
P/E Ratio-6.45
Dividend YieldN/A
Beta4.2
Vital Therapies logoVital Therapies, Inc., a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.

Receive VTL News and Ratings via Email

Sign-up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTL
CUSIPN/A
Phone858-673-6840

Debt

Debt-to-Equity RatioN/A
Current Ratio4.64
Quick Ratio4.64

Price-To-Earnings

Trailing P/E Ratio-6.45
Forward P/E Ratio-6.87
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book7.10

Profitability

EPS (Most Recent Fiscal Year)($1.31)
Net Income$-52,070,000.00
Net MarginsN/A
Return on Equity-96.73%
Return on Assets-83.38%

Miscellaneous

Employees97
Outstanding Shares42,370,000
Market Cap$338.95

Vital Therapies (NASDAQ:VTL) Frequently Asked Questions

What is Vital Therapies' stock symbol?

Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."

How were Vital Therapies' earnings last quarter?

Vital Therapies Inc (NASDAQ:VTL) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). View Vital Therapies' Earnings History.

When is Vital Therapies' next earnings date?

Vital Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vital Therapies.

What is the consensus analysts' recommendation for Vital Therapies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vital Therapies in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Vital Therapies stock?

Here are some recent quotes from research analysts about Vital Therapies stock:
  • 1. BTIG Research analysts commented, "and Therapies hosted an R&D day for analysts on May 24, during which senior management, internal R&D leaders, and two severe alcoholic hepatitis (sAH) clinical experts discussed ELAD’s mechanism of action and the pathophysiology of sAH. Much of the time was spent explaining the various factors underpinning the disease and ELAD’s impact on these pathways. While investors’ main priority remains seeing positive top-line data from VTL-308 in September, this insight into the disease will be valuable once the ELAD technology nears approval and commercialization." (5/28/2018)
  • 2. According to Zacks Investment Research, "Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. " (5/12/2018)

Who are some of Vital Therapies' key competitors?

Who are Vital Therapies' key executives?

Vital Therapies' management team includes the folowing people:
  • Mr. Russell J. Cox, CEO & Director (Age 55)
  • Dr. Duane D. Nash, Pres (Age 47)
  • Mr. Robert A. Ashley, Exec. VP & CTO (Age 60)
  • Mr. Michael V. Swanson M.B.A, CFO, Exec. VP & Teasurer (Age 63)
  • Mr. Aron P. Stern, Chief Admin. Officer (Age 64)

Has Vital Therapies been receiving favorable news coverage?

Media stories about VTL stock have trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vital Therapies earned a coverage optimism score of -0.06 on Accern's scale. They also gave news stories about the company an impact score of 47.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Vital Therapies?

Shares of VTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vital Therapies' stock price today?

One share of VTL stock can currently be purchased for approximately $8.45.

How big of a company is Vital Therapies?

Vital Therapies has a market capitalization of $338.95 million. The company earns $-52,070,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Vital Therapies employs 97 workers across the globe.

How can I contact Vital Therapies?

Vital Therapies' mailing address is 15010 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]


MarketBeat Community Rating for Vital Therapies (NASDAQ VTL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe VTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share (EPS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.